Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens

Next Previous
Trial Profile

Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Treosulfan (Primary) ; Busulfan
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Sponsors Medac

    • Most Recent Events

    • 12 Jan 2023 According to Medexus media release, the FDA continues to seek supporting information from Medac related to this study.
    • 16 Sep 2022 According to a Medexus media release, the company will provide an update to its shareholders and stakeholders once management knows whether the NDA resubmission has been accepted and is better able to assess the impact of this delay.
    • 16 Sep 2022 According to a Medexus media release, the U.S. Food and Drug Administration (FDA) has delivered to medac a second notice of incomplete response regarding medacs new drug application resubmission for treosulfan (NDA). The FDAs notice requests further supporting information from medac to complete medacs NDA resubmission but does not require submission of new clinical data.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top